Case-Based Roundtable Series

This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.

This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series explores tyrosine kinase inhibitor use and other treatments for patients with renal cell carcinoma, as discussed by participants at virtual live events.

This roundtable series discusses when to use chemotherapy and best dosing practices in patients with metastatic castration-resistant prostate cancer after treatment with docetaxel, as discussed by participants at virtual live events.

This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.

This roundtable series considers the use of immunotherapy-based combinations as treatment for non–small cell lung cancer, regardless of the patient’s PD-L1 expression, as discussed by participants at virtual live events.

This roundtable series evaluates the use of therapies such as monoclonal antibodies in advanced non–small cell lung cancer with high PD-L1 expression, as discussed by participants at virtual live events.

This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.

This roundtable series debates using newer JAK inhibitors as therapy for patients with myelofibrosis, considering the efficacy and safety profiles of the drugs, as discussed by participants at virtual live events.

This roundtable series assesses the use of Bruton tyrosine kinase inhibition for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, as discussed by participants at virtual live events.